Dyne Therapeutics
DYN

$36.41

6.03%

Market Cap: $3.66B

About: Dyne Therapeutics Inc is a biotechnology company focused on providing therapeutics for patients with genetically driven diseases. The company overcomes the limitations of muscle tissue delivery and modern oligonucleotide therapeutics for muscle diseases. The company is developing therapies for muscle disorders like Myotonic dystrophy, Duchenne muscular dystrophy, and Facioscapulohumeral muscular dystrophy. The company's product candidates are DYNE-101 and DYNE-251, both are in the ongoing phase 1/2 clinical trial.

Employees: 152

Healthcare Pharmaceutical Preparations

0

Funds holding %

of 6,710 funds

0

Analysts bullish %

of 8 analysts

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

527% more call options, than puts

Call options by funds: $6.11M | Put options by funds: $973K

118% more first-time investments, than exits

New positions opened: 48 | Existing positions closed: 22

70% more repeat investments, than reductions

Existing positions increased: 78 | Existing positions reduced: 46

44% more capital invested

Capital invested by funds: $2.73B [Q1] → $3.93B (+$1.19B) [Q2]

40% more funds holding in top 10

Funds holding in top 10: 10 [Q1] → 14 (+4) [Q2]

15% more funds holding

Funds holding: 168 [Q1] → 194 (+26) [Q2]

3.82% less ownership

Funds ownership: 117.49% [Q1] → 113.67% (-3.82%) [Q2]

See Fund Rankings

Research analyst outlook

8 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$43

18%

upside

Avg. target

$54

47%

upside

High target

$66

81%

upside

8 analyst ratings

8 positive

100%

0 neutral

0%

0 negative

0%

HC Wainwright & Co. Andrew Fein 45% 1-year accuracy 73 / 162 met price target	51%upside $55	Buy Reiterated	4 Sept 2024
Oppenheimer Francois Brisebois 60% 1-year accuracy 18 / 30 met price target	51%upside $55	Outperform Reiterated	3 Sept 2024
Stifel Paul Matteis 38% 1-year accuracy 6 / 16 met price target	81%upside $66	Buy Maintained	16 Aug 2024
Guggenheim Debjit Chattopadhyay 54% 1-year accuracy 7 / 13 met price target	37%upside $50	Buy Maintained	15 Aug 2024
Morgan Stanley Michael Ulz 47% 1-year accuracy 7 / 15 met price target	43%upside $52	Overweight Maintained	14 Aug 2024

See Analyst Rankings

Financial journalist opinion

Based on 65 articles about DYN published over the past 30 days

Investors Are Urged To Join The Schall Law Firm In An Inquiry Into Dyne Therapeutics, Inc. For Securities Law Violations

LOS ANGELES, CA / ACCESSWIRE / September 19, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Dyne Therapeutics, Inc. ("Dyne" or "the Company") (NASDAQ:DYN) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Investors Are Urged To Join The Schall Law Firm In An Inquiry Into Dyne Therapeutics, Inc. For Securities Law Violations

Bronstein, Gewirtz & Grossman, LLC Encourages Dyne Therapeutics, Inc. (DYN) Shareholders to Inquire about Securities Investigation

NEW YORK CITY, NY / ACCESSWIRE / September 19, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Dyne Therapeutics, Inc. ("Dyne" or "the Company") (NASDAQ:DYN). Investors who purchased Dyne securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/DYN.

Bronstein, Gewirtz & Grossman, LLC Encourages Dyne Therapeutics, Inc. (DYN) Shareholders to Inquire about Securities Investigation

Dyne Therapeutics Inc Is Being Investigated For Securities Fraud And The Schall Law Firm Wants Impacted Shareholders To Reach Out

LOS ANGELES, CA / ACCESSWIRE / September 18, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Dyne Therapeutics, Inc. ("Dyne" or "the Company") (NASDAQ:DYN) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Dyne Therapeutics Inc Is Being Investigated For Securities Fraud And The Schall Law Firm Wants Impacted Shareholders To Reach Out

Bronstein, Gewirtz & Grossman, LLC Is Investigating Dyne Therapeutics, Inc. (DYN) And Encourages Shareholders to Connect

NEW YORK CITY, NY / ACCESSWIRE / September 18, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Dyne Therapeutics, Inc. ("Dyne" or "the Company") (NASDAQ:DYN). Investors who purchased Dyne securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/DYN.

Bronstein, Gewirtz & Grossman, LLC Is Investigating Dyne Therapeutics, Inc. (DYN) And Encourages Shareholders to Connect

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc. - DYN

NEW YORK , Sept. 17, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Dyne Therapeutics, Inc. ("Dyne" or the "Company") (NASDAQ: DYN).

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc. - DYN

DYN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Dyne Therapeutics, Inc. and Encourages Investors to Contact the Firm!

NEW YORK, Sept. 17, 2024 (GLOBE NEWSWIRE) -- Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Dyne Therapeutics, Inc. (“Dyne” or “the Company”) (NASDAQ: DYN). Investors who purchased Dyne securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/DYN.

DYN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Dyne Therapeutics, Inc. and Encourages Investors to Contact the Firm!

The Schall Law Firm Is Looking Into Dyne Therapeutics, Inc. For Securities Related Infractions And Investors Are Invited To Join The Inquiry

LOS ANGELES, CA / ACCESSWIRE / September 17, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Dyne Therapeutics, Inc. ("Dyne" or "the Company") (NASDAQ:DYN) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

$The Schall Law Firm Is Looking Into Dyne Therapeutics, Inc. For Securities Related Infractions And Investors Are Invited To Join The Inquiry$

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Dyne Therapeutics, Inc. (DYN) And Encourages Shareholders to Reach Out

NEW YORK CITY, NY / ACCESSWIRE / September 17, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Dyne Therapeutics, Inc. ("Dyne" or "the Company") (NASDAQ:DYN). Investors who purchased Dyne securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/DYN.

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Dyne Therapeutics, Inc. (DYN) And Encourages Shareholders to Reach Out

DYN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Dyne Therapeutics, Inc. and Encourages Investors to Contact the Firm!

NEW YORK--(BUSINESS WIRE)---- $DYN #classaction--Attorney Advertising-- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Dyne Therapeutics, Inc. (“Dyne” or “the Company”) (NASDAQ: DYN). Investors who purchased Dyne securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/DYN. Investigation Details On September 3, 2024, Dyne issued a press release “announc[ing] new clinical data from its ongoing P.

DYN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Dyne Therapeutics, Inc. and Encourages Investors to Contact the Firm!

Shareholders Can Help The Schall Law Firm Investigate Dyne Therapeutics Inc For Possible Securities Fraud

LOS ANGELES, CA / ACCESSWIRE / September 16, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Dyne Therapeutics, Inc. ("Dyne" or "the Company") (NASDAQ:DYN) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Shareholders Can Help The Schall Law Firm Investigate Dyne Therapeutics Inc For Possible Securities Fraud

See News Rankings